323 related articles for article (PubMed ID: 29426067)
1. Reversal of Sepsis-Like Features of Neutrophils by Interleukin-1 Blockade in Patients With Systemic-Onset Juvenile Idiopathic Arthritis.
Ter Haar NM; Tak T; Mokry M; Scholman RC; Meerding JM; de Jager W; Verwoerd A; Foell D; Vogl T; Roth J; Leliefeld PHC; van Loosdregt J; Koenderman L; Vastert SJ; de Roock S
Arthritis Rheumatol; 2018 Jun; 70(6):943-956. PubMed ID: 29426067
[TBL] [Abstract][Full Text] [Related]
2. Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study.
Ter Haar NM; van Dijkhuizen EHP; Swart JF; van Royen-Kerkhof A; El Idrissi A; Leek AP; de Jager W; de Groot MCH; Haitjema S; Holzinger D; Foell D; van Loosdregt J; Wulffraat NM; de Roock S; Vastert SJ
Arthritis Rheumatol; 2019 Jul; 71(7):1163-1173. PubMed ID: 30848528
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study.
Vastert SJ; de Jager W; Noordman BJ; Holzinger D; Kuis W; Prakken BJ; Wulffraat NM
Arthritis Rheumatol; 2014 Apr; 66(4):1034-43. PubMed ID: 24757154
[TBL] [Abstract][Full Text] [Related]
4. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis.
Gattorno M; Piccini A; Lasigliè D; Tassi S; Brisca G; Carta S; Delfino L; Ferlito F; Pelagatti MA; Caroli F; Buoncompagni A; Viola S; Loy A; Sironi M; Vecchi A; Ravelli A; Martini A; Rubartelli A
Arthritis Rheum; 2008 May; 58(5):1505-15. PubMed ID: 18438814
[TBL] [Abstract][Full Text] [Related]
5. Neutrophils From Children With Systemic Juvenile Idiopathic Arthritis Exhibit Persistent Proinflammatory Activation Despite Long-Standing Clinically Inactive Disease.
Brown RA; Henderlight M; Do T; Yasin S; Grom AA; DeLay M; Thornton S; Schulert GS
Front Immunol; 2018; 9():2995. PubMed ID: 30619348
[No Abstract] [Full Text] [Related]
6. Proinflammatory Cytokine Environments Can Drive Interleukin-17 Overexpression by γ/δ T Cells in Systemic Juvenile Idiopathic Arthritis.
Kessel C; Lippitz K; Weinhage T; Hinze C; Wittkowski H; Holzinger D; Fall N; Grom AA; Gruen N; Foell D
Arthritis Rheumatol; 2017 Jul; 69(7):1480-1494. PubMed ID: 28296284
[TBL] [Abstract][Full Text] [Related]
7. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
[TBL] [Abstract][Full Text] [Related]
8. Impact of IL1RN Variants on Response to Interleukin-1 Blocking Therapy in Systemic Juvenile Idiopathic Arthritis.
Hinze C; Fuehner S; Kessel C; Wittkowski H; Lainka E; Baehr M; Hügle B; Haas JP; Ganser G; Weißbarth-Riedel E; Jansson A; Foell D
Arthritis Rheumatol; 2020 Mar; 72(3):499-505. PubMed ID: 31599092
[TBL] [Abstract][Full Text] [Related]
9. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis.
Kalliolias GD; Liossis SN
Expert Opin Investig Drugs; 2008 Mar; 17(3):349-59. PubMed ID: 18321234
[TBL] [Abstract][Full Text] [Related]
10. The limited role of interferon-γ in systemic juvenile idiopathic arthritis cannot be explained by cellular hyporesponsiveness.
Sikora KA; Fall N; Thornton S; Grom AA
Arthritis Rheum; 2012 Nov; 64(11):3799-808. PubMed ID: 22740319
[TBL] [Abstract][Full Text] [Related]
11. Early Treatment and IL1RN Single-Nucleotide Polymorphisms Affect Response to Anakinra in Systemic Juvenile Idiopathic Arthritis.
Pardeo M; Rossi MN; Pires Marafon D; Sacco E; Bracaglia C; Passarelli C; Caiello I; Marucci G; Insalaco A; Perrone C; Tulone A; Prencipe G; De Benedetti F
Arthritis Rheumatol; 2021 Jun; 73(6):1053-1061. PubMed ID: 33615724
[TBL] [Abstract][Full Text] [Related]
12. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial).
Quartier P; Allantaz F; Cimaz R; Pillet P; Messiaen C; Bardin C; Bossuyt X; Boutten A; Bienvenu J; Duquesne A; Richer O; Chaussabel D; Mogenet A; Banchereau J; Treluyer JM; Landais P; Pascual V
Ann Rheum Dis; 2011 May; 70(5):747-54. PubMed ID: 21173013
[TBL] [Abstract][Full Text] [Related]
13. Neutrophil activation signature in juvenile idiopathic arthritis indicates the presence of low-density granulocytes.
Ramanathan K; Glaser A; Lythgoe H; Ong J; Beresford MW; Midgley A; Wright HL
Rheumatology (Oxford); 2018 Mar; 57(3):488-498. PubMed ID: 29240923
[TBL] [Abstract][Full Text] [Related]
14. Anakinra in Systemic Juvenile Idiopathic Arthritis: A Single-center Experience.
Pardeo M; Pires Marafon D; Insalaco A; Bracaglia C; Nicolai R; Messia V; De Benedetti F
J Rheumatol; 2015 Aug; 42(8):1523-7. PubMed ID: 26034148
[TBL] [Abstract][Full Text] [Related]
15. Systemic Juvenile Idiopathic Arthritis: Diagnosis and Management.
Kumar S
Indian J Pediatr; 2016 Apr; 83(4):322-7. PubMed ID: 26916892
[TBL] [Abstract][Full Text] [Related]
16. IL1RN Variation Influences Both Disease Susceptibility and Response to Recombinant Human Interleukin-1 Receptor Antagonist Therapy in Systemic Juvenile Idiopathic Arthritis.
Arthur VL; Shuldiner E; Remmers EF; Hinks A; Grom AA; Foell D; Martini A; Gattorno M; Özen S; Prahalad S; Zeft AS; Bohnsack JF; Ilowite NT; Mellins ED; Russo R; Len C; Oliveira S; Yeung RSM; Rosenberg AM; Wedderburn LR; Anton J; Haas JP; Rösen-Wolff A; Minden K; Szymanski AM; ; Thomson W; Kastner DL; Woo P; Ombrello MJ
Arthritis Rheumatol; 2018 Aug; 70(8):1319-1330. PubMed ID: 29609200
[TBL] [Abstract][Full Text] [Related]
17. Distinct Gene Expression Signatures Characterize Strong Clinical Responders Versus Nonresponders to Canakinumab in Children With Systemic Juvenile Idiopathic Arthritis.
Verweyen EL; Pickering A; Grom AA; Schulert GS
Arthritis Rheumatol; 2021 Jul; 73(7):1334-1340. PubMed ID: 33452871
[TBL] [Abstract][Full Text] [Related]
18. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
[TBL] [Abstract][Full Text] [Related]
19. Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis.
Barnes MG; Grom AA; Thompson SD; Griffin TA; Pavlidis P; Itert L; Fall N; Sowders DP; Hinze CH; Aronow BJ; Luyrink LK; Srivastava S; Ilowite NT; Gottlieb BS; Olson JC; Sherry DD; Glass DN; Colbert RA
Arthritis Rheum; 2009 Jul; 60(7):2102-12. PubMed ID: 19565513
[TBL] [Abstract][Full Text] [Related]
20. Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans.
Kimura Y; Grevich S; Beukelman T; Morgan E; Nigrovic PA; Mieszkalski K; Graham TB; Ibarra M; Ilowite N; Klein-Gitelman M; Onel K; Prahalad S; Punaro M; Ringold S; Toib D; Van Mater H; Weiss JE; Weiss PF; Schanberg LE;
Pediatr Rheumatol Online J; 2017 Apr; 15(1):23. PubMed ID: 28399931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
